What's Going On With Huamacyte Shares Tuesday?
Humacyte, Inc. 
HUMA stock is trending on Tuesday. In July, the company has so far added Dr. John P. Bamforth and Dr. Keith Anthony to its Board of Directors, entered a license agreement with Pluristyx and received Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for its Acellular Tissue Engineered Vessel.
The Details: Humacyte acquired a license for Pluristyx’s PluriBank induced Pluripotent Stem Cell (iPSC) line to use as starting materials in the production of insulin-producing cells for their BioVascular Pancreas (BVP) product candidate.
The BVP aims to treat type 1 diabetes by facilitating the delivery and survival of insulin-producing islets within the body.
“The combination of Humacyte’s Acellular Tissue Engineered Vessel (ATEV) with insulin-producing cells derived from Pluristyx’s best-in-class iPSC lines brings us one step closer to curing insulin dependent diabetes,” said Benjamin Fryer, Pluristyx’s CEO.
“We are excited to assist therapeutic developers in using clinical-grade PluriBank iPSC starting materials.”
At the start of the month, the company received RMAT designation for the application of Humacyte’s ATEV in patients with Advanced Peripheral Artery Disease (PAD). This treatment is particularly beneficial for PAD patients who may not have suitable veins for traditional lower leg bypass procedures.
The ATEV is an implantable conduit designed for blood vessel replacement and repair. It has demonstrated low infection rates in clinical trials and is readily available off-the-shelf for immediate surgical use.
Analyst Changes: Multiple analysts have issued price target adjustments throughout July.
- BTIG analyst Ryan Zimmerman maintains Humacyte with a Buy and raises the price target from $8 to $11.
- Cantor Fitzgerald analyst Kristen Kluska reiterates Humacyte with a Overweight and maintains $7 price target.
- Benchmark analyst Bruce Jackson reiterates Humacyte with a Buy and maintains $15 price target.
How To Buy Humacyte Stock
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Humacyte HUMA's case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
HUMA Price Action: At the time of publication, Humacyte stock is trading 5.8% higher at $8.89 per data from Benzinga Pro.
Image: Michal Jarmoluk from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.